Helicobacter pylori News and Research

RSS
Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

Irritable bowel syndrome is linked to bacterial biofilms in the gut

Irritable bowel syndrome is linked to bacterial biofilms in the gut

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

Host protein mimicry of SARS-CoV-2 receptor binding motif

Host protein mimicry of SARS-CoV-2 receptor binding motif

Cholestenone could be a new antibacterial drug against H. pylori

Cholestenone could be a new antibacterial drug against H. pylori

Study finds a bacterial molecule that may be key to fighting gastric cancer

Study finds a bacterial molecule that may be key to fighting gastric cancer

Asymptomatic SARS-CoV-2 individuals with blood group AB at highest risk

Asymptomatic SARS-CoV-2 individuals with blood group AB at highest risk

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new method to determine how carcinogenic bacteria reach their targets

A new method to determine how carcinogenic bacteria reach their targets

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Regular walnut intake may help protect against negative outcomes associated with H. pylori infection

Regular walnut intake may help protect against negative outcomes associated with H. pylori infection

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

P2 COVID-19 study shows no material safety differences between opaganib and control arms

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

RedHill Biopharma announces promising preliminary results from opaganib study

RedHill Biopharma announces promising preliminary results from opaganib study